Adial Pharmaceuticals Inc (ADIL) concluded trading on Thursday at a closing price of $0.41, with 6.63 million shares of worth about $2.72 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -61.99% during that period and on July 10, 2025 the price saw a gain of about 28.61%. Currently the company’s common shares owned by public are about 15.78M shares, out of which, 14.42M shares are available for trading.
Stock saw a price change of 24.20% in past 5 days and over the past one month there was a price change of -28.67%. Year-to-date (YTD), ADIL shares are showing a performance of -62.03% which decreased to -59.41% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.22 but also hit the highest price of $3.00 during that period. The average intraday trading volume for Adial Pharmaceuticals Inc shares is 8.38 million. The stock is currently trading 26.30% above its 20-day simple moving average (SMA20), while that difference is down -22.58% for SMA50 and it goes to -49.74% lower than SMA200.
Adial Pharmaceuticals Inc (NASDAQ: ADIL) currently have 15.78M outstanding shares and institutions hold larger chunk of about 3.64% of that.
The stock has a current market capitalization of $6.47M and its 3Y-monthly beta is at 0.97. It has posted earnings per share of -$1.62 in the same period. It has Quick Ratio of 1.99 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ADIL, volatility over the week remained 12.86% while standing at 20.39% over the month.
Analysts are in expectations that Adial Pharmaceuticals Inc (ADIL) stock would likely to be making an EPS of -0.22 in the current quarter, while forecast for next quarter EPS is -0.09 and it is -1.0 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.22 which is -0.22 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.59 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 79.78%.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Rodman & Renshaw on November 14, 2024 offering a Buy rating for the stock and assigned a target price of $8 to it. Coverage by Maxim Group stated Adial Pharmaceuticals Inc (ADIL) stock as a Buy in their note to investors on October 30, 2018, suggesting a price target of $5 for the stock.
